Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -9.56%117.02B | 17.63%505.98B | -10.82%108.52B | 1.29%125.77B | 31.07%142.3B | 70.83%129.39B | 38.26%430.16B | 29.43%121.68B | 78.10%124.17B | 62.28%108.57B |
Cost of revenue | -12.21%106.2B | 27.35%506.14B | 22.06%137.3B | 1.91%114.87B | 29.09%133.02B | 74.77%120.96B | 37.85%397.45B | 27.71%112.48B | 74.01%112.71B | 68.44%103.04B |
Gross profit | 28.40%10.82B | -100.48%-157M | -412.86%-28.78B | -4.83%10.9B | 68.02%9.29B | 29.14%8.43B | 43.50%32.71B | 54.95%9.2B | 131.81%11.46B | -3.46%5.53B |
Operating expense | 32.44%4.41B | 1.76%14.85B | -13.85%4.05B | -1.70%3.88B | 12.61%3.59B | 20.79%3.33B | 19.13%14.59B | 28.11%4.7B | 33.32%3.95B | 8.55%3.19B |
Operating profit | 25.76%6.41B | -182.83%-15.01B | -829.61%-32.83B | -6.47%7.02B | 143.50%5.7B | 35.24%5.1B | 71.81%18.12B | 98.37%4.5B | 279.14%7.51B | -16.10%2.34B |
Net non-operating interest income (expenses) | 34.44%2.63B | 412.18%10.56B | 242.11%4.49B | 208.28%2.01B | 1,216.88%2.11B | 3,251.61%1.95B | 459.06%2.06B | 1,201.68%1.31B | 392.38%652M | 202.56%160M |
Non-operating interest income | 31.31%2.79B | 280.39%11.25B | 199.68%4.66B | 150.75%2.18B | 501.05%2.28B | 1,290.20%2.13B | 869.84%2.96B | 1,394.23%1.55B | --871M | 512.90%380M |
Non-operating interest expense | -4.05%166M | -22.41%696M | -29.22%172M | -20.55%174M | -19.55%177M | -19.53%173M | 2.05%897M | 8.97%243M | -1.79%219M | 0.92%220M |
Net investment income | -559.19%-3.59B | -185.55%-533M | 63.81%-351M | -50.16%471M | -116.22%-109M | -2,166.67%-544M | -65.16%623M | -245.21%-970M | -13.70%945M | 612.98%672M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -745.45%-71M | 0 | 0 | -1,520.00%-71M | 0 | -84.51%11M | -126.38%-43M | 94.57%-5M | 5M | |
Income from associates and other participating interests | 0 | -44.31%-596M | -312.50%-429M | 53.33%-28M | 27.10%-78M | 57.04%-61M | -28.66%-413M | 20.00%-104M | 49.15%-60M | -91.07%-107M |
Special income (charges) | 360.00%207M | -225.96%-626M | -234.07%-665M | 0 | -6M | 45M | 102.39%497M | 196.50%496M | -99.22%1M | 0 |
Less:Restructuring and mergern&acquisition | ---- | --0 | ---- | ---- | ---- | ---- | --94M | ---- | ---- | ---- |
Less:Other special charges | -360.00%-207M | 205.92%626M | 212.71%665M | --0 | --6M | ---45M | -102.91%-591M | -770.45%-590M | ---- | ---- |
Other non-operating income (expenses) | 81.25%29M | 287.50%120M | 138.78%19M | 280.00%45M | 53.85%40M | 200.00%16M | -966.67%-64M | -250.00%-49M | -219.05%-25M | 30.00%26M |
Income before tax | -12.58%5.69B | -129.57%-6.16B | -679.46%-29.77B | 5.59%9.52B | 144.72%7.58B | 81.84%6.51B | 324.98%20.83B | 121.33%5.14B | 223.00%9.02B | 25.59%3.1B |
Income tax | -1.76%1.56B | 51.70%8.54B | -38.55%1.52B | -3.39%1.74B | 11,634.38%3.69B | 14.67%1.59B | 57.72%5.63B | 68.27%2.48B | 59.01%1.8B | -105.47%-32M |
Net income | -16.05%4.13B | -196.70%-14.7B | -1,275.80%-31.29B | 7.82%7.78B | 24.29%3.89B | 124.24%4.92B | 218.49%15.2B | 213.80%2.66B | 334.90%7.22B | 66.26%3.13B |
Net income continuous operations | -16.07%4.13B | -196.70%-14.7B | -1,276.28%-31.29B | 7.83%7.78B | 24.26%3.89B | 124.18%4.92B | 218.50%15.2B | 213.31%2.66B | 334.90%7.22B | 66.35%3.13B |
Noncontrolling interests | 210.81%115M | 9,333.33%1.13B | 4,580.00%234M | 11,933.33%722M | 3,575.00%139M | 640.00%37M | 106.06%12M | 102.78%5M | 160.00%6M | -100.00%-4M |
Net income attributable to the company | -17.77%4.02B | -204.24%-15.83B | -1,287.31%-31.52B | -2.09%7.06B | 19.69%3.75B | 123.01%4.88B | 220.25%15.19B | 158.02%2.66B | 331.94%7.21B | 66.30%3.13B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -17.77%4.02B | -204.24%-15.83B | -1,287.31%-31.52B | -2.09%7.06B | 19.69%3.75B | 123.01%4.88B | 220.25%15.19B | 158.02%2.66B | 331.94%7.21B | 66.30%3.13B |
Gross dividend payment | ||||||||||
Basic earnings per share | -19.95%13.48 | -236.96%-69.22 | -1,603.28%-123.72 | -2.29%25.22 | 23.54%12.44 | 161.90%16.84 | 188.85%50.54 | 324.23%8.23 | 483.94%25.81 | 91.81%10.07 |
Diluted earnings per share | -19.47%3.93 | -546.87%-69.22 | -1,603.28%-123.72 | -2.29%25.22 | 23.54%12.44 | 118.83%4.88 | 127.23%15.49 | 324.23%8.23 | 483.94%25.81 | 91.81%10.07 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |